Free tool
FAERS Monitor: Dificid
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201699 or its brand name (Dificid, Fidaxomicin). Reports on generic versions are filed under their own applications.
Reports
2,417
Serious
1,442
60% of reports
Hospitalization
758
Death reported
258
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- clostridium difficile infection484
- drug ineffective419
- diarrhoea354
- disease recurrence179
- clostridium difficile colitis162
- off label use135
- nausea125
- treatment failure120
- abdominal pain88
- no adverse event86
- pyrexia78
- vomiting73
- death71
- fatigue63
- product dose omission issue56
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 15 |
| 2012 | 36 |
| 2013 | 276 |
| 2014 | 122 |
| 2015 | 162 |
| 2016 | 121 |
| 2017 | 99 |
| 2018 | 147 |
| 2019 | 195 |
| 2020 | 192 |
| 2021 | 156 |
| 2022 | 170 |
| 2023 | 160 |
| 2024 | 206 |
| 2025 | 220 |
| 2026 | 140 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,742 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| clostridium difficile infectionSignal | 484 | 197.3 | 182.0 | 92,339 |
| clostridium difficile colitisSignal | 162 | 135.0 | 116.2 | 21,101 |
| disease recurrenceSignal | 179 | 32.9 | 28.5 | 5,489 |
| treatment failureSignal | 120 | 12.6 | 10.6 | 1,276 |
| diarrhoeaSignal | 354 | 4.8 | 4.3 | 1,085 |
| no adverse eventSignal | 86 | 4.1 | 3.4 | 203 |
| abdominal painSignal | 88 | 3.3 | 2.7 | 140 |
| drug ineffectiveSignal | 419 | 2.8 | 2.5 | 502 |
| pyrexia | 78 | 2.0 | 1.6 | 36 |
| product dose omission issue | 56 | 1.7 | 1.3 | 14 |
| nausea | 125 | 1.4 | 1.2 | 13 |
| vomiting | 73 | 1.4 | 1.1 | 6 |
| off label use | 135 | 1.3 | 1.1 | 12 |
| death | 71 | 0.7 | 0.6 | 8 |
| fatigue | 63 | 0.7 | 0.6 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.